DEXCOM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 110.3 USD | -0.24% |
|
-5.43% | -11.10% |
| 06-25 | Out with AI, in with defensive stocks |  |
| 06-20 | Glucotrack Announces the Appointment of Andy Balo to Board of Directors | CI |
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
110.3
USD
Average target price
150.3
USD
Spread / Average Target
+36.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.10% | 43.97B | |
| -4.16% | 183B | |
| -2.39% | 104B | |
| -4.08% | 68.18B | |
| +16.04% | 47.14B | |
| +6.87% | 40.95B | |
| +17.63% | 31.05B | |
| -8.10% | 24.11B | |
| +12.09% | 24.05B | |
| -11.08% | 22.31B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- BTIG Adjusts DexCom's Price Target to $156 From $150
